Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Body mass index influence interferon-beta treatment response in multiple sclerosis.
Daily fingolimod administration may cause lymphopenia but alternate-day administration may be too little to inhibit disease activity.
[Pathology, diagnosis, and treatment of combined central and peripheral demyelination].
Pre-Existing Mature Oligodendrocytes Do Not Contribute to Remyelination following Toxin-Induced Spinal Cord Demyelination.
Famvir | Where To Get Buy
Event-related potentials and cognitive performance in multiple sclerosis patients with fatigue.
Preliminary Observations on Sensitivity and Specificity of Magnetization Transfer Asymmetry for Imaging Myelin of Rat Brain at High Field.
Bypassing hazard of housekeeping genes: their evaluation in rat granule neurons treated with cerebrospinal fluid of multiple sclerosis subjects.
Impaired oligodendrocyte maturation in preterm infants: Potential therapeutic targets.
Good cardiac safety in patients with relapsing remitting multiple sclerosis upon first fingolimod dose.
A white matter lesion-filling approach to improve brain tissue volume measurements.
Thoracic sensory level as a false localizing sign in cervical spinal cord and brain lesions.
Development of A Screening Tool to Support Identification of Patients With Secondary Progressive Multiple Sclerosis (Spms).
[Current and historical concept of neuromyelitis optica].
Predictive Value of Imaging Markers at Multiple Sclerosis Disease Onset Based on Gadolinium- and USPIO-Enhanced MRI and Machine Learning.
An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy.
Polymorphisms of Immunoglobulin G Fc Receptors in Pediatric Guillain-Barré Syndrome.
The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
Schwann cells-axon interaction in myelination.
Mesenchymal stem cells attenuate MRI-identifiable injury, protect white matter, and improve long-term functional outcomes after neonatal focal stroke in rats.
X-ray radiation and the risk of multiple sclerosis: Do the site and dose of exposure matter?
Lung inflammation stalls Th17 cell migration en route to the central nervous system during the development of experimental autoimmune encephalomyelitis.
Olesoxime favors oligodendrocyte differentiation through a functional interplay between mitochondria and microtubules.
Clinical and epidemiological profiles of non-traumatic myelopathies.
Healthcare Costs Associated with Patients Diagnosed with Relapsing Remitting Multiple Sclerosis.
Pages
« first
‹ previous
…
720
721
722
723
724
725
726
727
728
…
next ›
last »